Benjamin Palleiko is Chief Executive Officer of KalVista Pharmaceuticals, Inc. (KALV). The company reported total compensation of $6,772,197 for fiscal year 2024.
| Salary | $580,441 |
|---|---|
| Bonus | $389,138 |
| Stock awards | $5,486,659 |
| Option awards | $302,468 |
| Non-equity incentive plan | $0 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $13,491 |
| Total | $6,772,197 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure KalVista Pharmaceuticals, Inc. filed August 21, 2025, accession 0001193125-25-185353.
| Fiscal year | Role | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|---|
| FY2024 | Chief Executive Officer | $580,441 | $389,138 | $5,486,659 | $302,468 | $0 | $0 | $13,491 | $6,772,197 |
| FY2023 | Chief Executive Officer | $514,500 | $180,075 | $1,524,224 | $189,421 | — | — | $12,527 | $2,420,747 |
Totals as disclosed in each year's own compensation disclosure for KalVista Pharmaceuticals, Inc..
| Named executive officer | Role | FY2024 total |
|---|---|---|
| Benjamin Palleiko this page | Chief Executive Officer | $6,772,197 |
| Brian Piekos | Chief Financial Officer | $2,144,133 |
| Paul Audhya | Chief Medical Officer | $1,833,974 |
The company's named executive officers for fiscal year 2024, and what it reported for each. See the full KalVista Pharmaceuticals, Inc. compensation brief.
Benjamin Palleiko's compensation sits inside KalVista Pharmaceuticals, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.
The KalVista Pharmaceuticals, Inc. (KALV) compensation brief